Patents Assigned to Cell>Point LLC
  • Patent number: 10814013
    Abstract: Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.
    Type: Grant
    Filed: July 31, 2012
    Date of Patent: October 27, 2020
    Assignees: The Board of Regents of the University of Texas System, Cell>Point, LLC
    Inventors: David J. Yang, Dongfang Yu, Andrew S. Thompson, F. David Rollo
  • Publication number: 20040166058
    Abstract: The invention provides, in a general sense, a new labeling strategy employing compounds that are are N2S2 chelates conjugated to a targeting ligand, wherein the targeting ligand is a disease cell cycle targeting compound, a tumor angiogenesis targeting ligand, a tumor apoptosis targeting ligand, a disease receptor targeting ligand, amifostine, angiostatin, monoclonal antibody C225, monoclonal antibody CD31, monoclonal antibody CD40, capecitabine, COX-2, deoxycytidine, fullerene, herceptin, human serum albumin, lactose, leuteinizing hormone, pyridoxal, quinazoline, thalidomide, transferrin, or trimethyl lysine. The present invention also pertains to kits employing the compounds of interest, and methods of assessing the pharmacology of an agent of interest using the present compounds.
    Type: Application
    Filed: November 7, 2003
    Publication date: August 26, 2004
    Applicants: Board of Regents, The University of Texas System, Cell>Point LLC
    Inventors: David J. Yang, Dong-Fang Yu, Chang-Sok Oh, Jerry L. Bryant